



### Executive Summary

*For Healthcare and Addiction Professionals, Policymakers, Patients, and Families*

The Executive Summary of this **Treatment Improvement Protocol** provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.

### TIP Navigation

#### Executive Summary

*For healthcare and addiction professionals, policymakers, patients, and families*

#### Part 1: Introduction to Medications for Opioid Use Disorder Treatment

*For healthcare and addiction professionals, policymakers, patients, and families*

#### Part 2: Addressing Opioid Use Disorder in General Medical Settings

*For healthcare professionals*

#### Part 3: Pharmacotherapy for Opioid Use Disorder

*For healthcare professionals*

#### Part 4: Partnering Addiction Treatment Counselors With Clients and Healthcare Professionals

*For healthcare and addiction professionals*

#### Part 5: Resources Related to Medications for Opioid Use Disorder

*For healthcare and addiction professionals, policymakers, patients, and families*







## Contents

<b>Foreword</b> .....	ES-iv
<b>TIP 63 Update</b> .....	ES-iv
<b>Introduction</b> .....	ES-1
<b>Overall Key Messages</b> .....	ES-1
<b>Content Overview</b> .....	ES-3
Part 1: Introduction to Medications for Opioid Use Disorder Treatment .....	ES-3
Part 2: Addressing Opioid Use Disorder in General Medical Settings .....	ES-4
Part 3: Pharmacotherapy for Opioid Use Disorder .....	ES-4
Part 4: Partnering Addiction Treatment Counselors With Clients and Healthcare Professionals .....	ES-5
Part 5: Resources Related to Medications for Opioid Use Disorder .....	ES-5
<b>Notes</b> .....	ES-7
<b>TIP Development Participants</b> .....	ES-9
Expert Panelists .....	ES-9
Scientific Reviewers .....	ES-10
Field Reviewers .....	ES-10
<b>Publication Information</b> .....	ES-12



## Foreword

The Substance Abuse and Mental Health Services Administration (SAMHSA) is the U.S. Department of Health and Human Services agency that leads public health efforts to reduce the impact of substance abuse and mental illness on America's communities. An important component of SAMHSA's work is focused on dissemination of evidence-based practices and providing training and technical assistance to healthcare practitioners on implementation of these best practices.

The Treatment Improvement Protocol (TIP) series contributes to SAMHSA's mission by providing science-based, best-practice guidance to the behavioral health field. TIPs reflect careful consideration of all relevant clinical and health services research, demonstrated experience, and implementation requirements. Select nonfederal clinical researchers, service providers, program administrators, and patient advocates comprising each TIP's consensus panel discuss these factors, offering input on the TIP's specific topics in their areas of expertise to reach consensus on best practices. Field reviewers then assess draft content and the TIP is finalized.

The talent, dedication, and hard work that TIP panelists and reviewers bring to this highly participatory process have helped bridge the gap between the promise of research and the needs of practicing clinicians and administrators to serve, in the most scientifically sound and effective ways, people in need of care and treatment of mental and substance use disorders. My sincere thanks to all who have contributed their time and expertise to the development of this TIP. It is my hope that clinicians will find it useful and informative to their work.

### **Elinore F. McCance-Katz, M.D., Ph.D.**

Assistant Secretary for Mental Health and Substance Use  
U.S. Department of Health and Human Services  
Substance Abuse and Mental Health Services Administration

## TIP 63 Update

To ensure that the content of this TIP is as up to date and as useful to readers as possible, SAMHSA, in January 2020, revised certain areas of all five parts. These changes will help provide readers with the latest information needed to understand medications for opioid use disorder. These changes included the following:

- Updating statistics from SAMHSA, the Centers for Disease Control and Prevention, and other health authorities on opioid-related deaths, overdoses, accidents, and hospitalizations.
- Updating the expanded list of other qualifying practitioners who are eligible to apply for a waiver to prescribe buprenorphine (i.e., clinical nurse specialists, certified registered nurse anesthetists, and certified nurse midwives).
- Clarifying that buprenorphine is available in an extended-release injection formulation.
- Adding information about the use of subdermal formulations of buprenorphine (i.e., Probuphine and Sublocade).
- Adding information about possible clinical interactions between formulations of buprenorphine and naltrexone with various other medications and products.
- Improving the language to make clear the importance of testing for HIV and hepatitis C.
- Updating recommendations from the U.S. Preventive Services Task Force on performing drug screening for adults in primary care settings.
- Removing or replacing broken hyperlinks to online resources.

## Executive Summary

The goal of treatment for opioid addiction or opioid use disorder (OUD) is remission of the disorder leading to lasting recovery. Recovery is a process of change through which individuals improve their health and wellness, live self-directed lives, and strive to reach their full potential.<sup>1</sup> This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD.

### Introduction

Our nation faces a crisis of overdose deaths from opioids, including heroin, illicit fentanyl, and prescription opioids. These deaths represent a mere fraction of the total number of Americans harmed by opioid misuse and addiction. Many Americans now suffer daily from a chronic medical illness called “opioid addiction” or OUD (see the Glossary in Part 5 of this TIP for definitions). Healthcare professionals, treatment providers, and policymakers have a responsibility to expand access to evidence-based, effective care for people with OUD.



Estimated cost of the **OPIOID EPIDEMIC** was **\$504 BILLION** in 2015.<sup>2</sup>

An expert panel developed the TIP’s content based on a review of the literature and on their extensive experience in the field of addiction treatment. Other professionals also generously contributed their time and commitment to this project.

An estimated **1.7M AMERICANS** have OUD related to opioid painkillers; **526K** have heroin-related OUD.<sup>3</sup>



The TIP is divided into parts so that readers can easily find the material they need. Part 1 is a general introduction to providing medications for OUD and issues related to providing that treatment. Some readers may prefer to go directly to those parts most relevant to their areas of interest, but everyone is encouraged to read Part 1 to establish a shared understanding of key facts and issues covered in detail in this TIP.

Following is a summary of the TIP’s overall main points and brief summaries of each of the five TIP parts.


### Overall Key Messages

#### **Addiction is a chronic, treatable illness.**

Opioid addiction, which generally corresponds with moderate to severe forms of OUD, often requires continuing care for effective treatment rather than an episodic, acute-care treatment approach.



Opioid overdose caused **46,800 DEATHS** nationwide in 2018—this exceeded the # caused by motor vehicle crashes.<sup>4,5</sup>



**General principles of good care for chronic diseases can guide OUD treatment.**

Approaching OUD as a chronic illness can help providers deliver care that helps patients stabilize, achieve remission of symptoms, and establish and maintain recovery.

**Patient-centered care empowers patients with information that helps them make better treatment decisions with the healthcare professionals involved in their care.**

Patients should receive information from their healthcare team that will help them understand OUD and the options for treating it, including treatment with FDA-approved medication.

**Patients with OUD should have access to mental health services as needed, medical care, and addiction counseling, as well as recovery support services, to supplement treatment with medication.**

**The words you use to describe OUD and an individual with OUD are powerful.** This TIP defines, uses, and encourages providers to adopt terminology that will not reinforce prejudice, negative attitudes, or discrimination.

**There is no “one size fits all” approach to OUD treatment.** Many people with OUD benefit from treatment with medication for varying lengths of time, including lifelong treatment. Ongoing outpatient medication treatment for OUD is linked to better retention and outcomes

than treatment without medication. Even so, some people stop using opioids on their own; others recover through support groups or specialty treatment with or without medication.

**The science demonstrating the effectiveness of medication for OUD is strong.** For example, methadone, extended-release injectable naltrexone (XR-NTX), and buprenorphine were each found to be more effective in reducing illicit opioid use than no medication in randomized clinical trials, which are the gold standard for demonstrating efficacy in clinical medicine.<sup>6,7,8,9,10</sup> Methadone and buprenorphine treatment have also been associated with reduced risk of overdose death.<sup>11,12,13,14,15</sup>

**This doesn’t mean that remission and recovery occur only through medication.** Some people achieve remission without OUD medication, just as some people can manage type 2 diabetes with exercise and diet alone. But just as it is inadvisable to deny people with diabetes the medication they need to help manage their illness, it is also not sound medical practice to deny people with OUD access to FDA-approved medications for their illness.

**Medication for OUD should be successfully integrated with outpatient and residential treatment.** Some patients may benefit from different levels of care at different points in their lives, such as outpatient counseling, intensive outpatient treatment, inpatient treatment, or long-term therapeutic communities. Patients treated in these settings should have access to OUD medications.

**2 MILLION** people in the U.S., ages 12 and older, had OUD involving **PRESCRIPTION OPIOIDS, HEROIN,** or both in 2018.<sup>16</sup>



**Patients treated with medications for OUD can benefit from individualized psychosocial supports.** These can be offered by patients' healthcare providers in the form of medication management and supportive counseling and/or by other providers offering adjunctive addiction counseling, recovery coaching, mental health services, and other services that may be needed by particular patients.

**Expanding access to OUD medications is an important public health strategy.**<sup>17</sup> The gap between the number of people needing opioid addiction treatment and the capacity to treat them with OUD medication is substantial. In 2012, the gap was estimated at nearly 1 million people, with about 80 percent of opioid treatment programs (OTPs) nationally operating at 80 percent capacity or greater.<sup>18</sup>

**Improving access to treatment with OUD medications is crucial to closing the wide gap between treatment need and treatment availability, given the strong evidence of effectiveness for such treatments.**<sup>19</sup>

**Data indicate that medications for OUD are cost effective and cost beneficial.**<sup>20,21</sup>

## Content Overview

The TIP is divided into parts to make the material more accessible according to the reader's interests.

### Part 1: Introduction to Medications for Opioid Use Disorder Treatment

This part lays the groundwork for understanding treatment concepts discussed later in this TIP. The intended audience includes:

- Healthcare professionals (physicians, nurse practitioners, physician assistants, and, until October 1, 2023, clinical nurse specialists, certified registered nurse anesthetists, and certified nurse midwives).
- Professionals who offer addiction counseling or mental health services.

### OPIOID-RELATED EMERGENCY DEPARTMENT

visits more than doubled  
from 2005 to 2016.<sup>22,23</sup>




- Peer support specialists.
- People needing treatment and their families.
- People in remission or recovery and their families.
- Hospital administrators.
- Policymakers.

In Part 1, readers will learn that:

- Increasing opioid overdose deaths, illicit opioid use, and prescription opioid misuse constitute a public health crisis.
- OUD medications reduce illicit opioid use, retain people in treatment, and reduce risk of opioid overdose death better than treatment with placebo or no medication.
- Only physicians; nurse practitioners; physician assistants; and, until October 1, 2023, clinical nurse specialists, certified registered nurse anesthetists, and certified nurse midwives can prescribe buprenorphine for OUD. They must get a federal waiver to do so.
- Only federally certified, accredited OTPs can dispense methadone to treat OUD. OTPs can administer and dispense buprenorphine without a federal waiver.
- Any prescriber can offer naltrexone.
- OUD medication can be taken on a short- or long-term basis, including as part of medically supervised withdrawal and as maintenance treatment.
- Patients taking medication for OUD are considered to be in recovery.
- Several barriers contribute to the underuse of medication for OUD.



**EVERYONE AGES 15 TO 65** should be tested at least **ONCE** for **HIV**. Persons at **HIGHER RISK**, such as people who use **DRUGS** by injection, should be tested **ANNUALLY**.



Anyone who is injecting or has ever **INJECTED DRUGS**, even **ONCE**, no matter how long ago, should be **TESTED** for **HEPATITIS C**, regardless of their intention to seek **TREATMENT** for SUD.<sup>24,25</sup>

## Part 2: Addressing Opioid Use Disorder in General Medical Settings

This part offers guidance on OUD screening, assessment, treatment, and referral. Part 2 is for healthcare professionals working in general medical settings with patients who have or are at risk for OUD.

In Part 2, readers will learn that:

- All healthcare practices should screen for alcohol, tobacco, and other substance misuse (including opioid misuse).
- Validated screening tools, symptom surveys, and other resources are readily available; this part lists many of them.

- When patients screen positive for risk of harm from substance use, practitioners should assess them using tools that determine whether substance use meets diagnostic criteria for a substance use disorder (SUD).
- Thorough assessment should address patients' medical, social, SUD, and family histories.
- Laboratory tests can inform treatment planning.
- Practitioners should develop treatment plans or referral strategies (if onsite SUD treatment is unavailable) for patients who need SUD treatment.

## Part 3: Pharmacotherapy for Opioid Use Disorder

This part offers information and tools for health-care professionals who prescribe, administer, or dispense OUD medications or treat other illnesses in patients who take these medications. It provides guidance on the use of buprenorphine, methadone, and naltrexone by healthcare professionals in:

- General medical settings, including hospitals.
- Office-based opioid treatment settings.
- Specialty addiction treatment programs, including OTPs.

In Part 3, readers will learn that:

- OUD medications are safe and effective when used appropriately.

**OPIOID-RELATED**  
inpatient hospital stays  
**INCREASED 117%**  
nationally from 2005 to 2016.<sup>26,27</sup>





- OUD medications can help patients reduce or stop illicit opioid use and improve their health and functioning.
- Pharmacotherapy should be considered for all patients with OUD. Opioid pharmacotherapies should be reserved for those with moderate-to-severe OUD with physical dependence.
- Patients with OUD should be informed of the risks and benefits of pharmacotherapy, treatment without medication, and no treatment.
- Patients should be advised on where and how to get treatment with OUD medication.
- Doses and schedules of pharmacotherapy must be individualized.

#### Part 4: Partnering Addiction Treatment Counselors With Clients and Healthcare Professionals

This part recommends ways that addiction treatment counselors can collaborate with healthcare professionals to support client-centered, trauma-informed OUD treatment and recovery. It also serves as a quick guide to medications that can treat OUD and presents strategies for clear communication with prescribers, creation of supportive environments for clients who take OUD medication, and ways to address other common counseling concerns when working with this population.

In Part 4, readers will learn that:

- Many patients taking OUD medication benefit from counseling as part of treatment.
- Counselors play the same role for clients with OUD who take medication as for clients with any other SUD.
- Counselors help clients recover by addressing the challenges and consequences of addiction.
- OUD is often a chronic illness requiring ongoing communication among patients and providers to ensure that patients fully benefit from both pharmacotherapy and psychosocial treatment and support.

**OPIOID ADDICTION**  
is linked with high rates of  
**ILLEGAL ACTIVITY** and  
**INCARCERATION.**<sup>28,29</sup>



- OUD medications are safe and effective when prescribed and taken appropriately.
- Medication is integral to recovery for many people with OUD. Medication usually produces better treatment outcomes than outpatient treatment without medication.
- Supportive counseling environments for clients who take OUD medication can promote treatment and help build recovery capital.

#### Part 5: Resources Related to Medications for Opioid Use Disorder

This part has a glossary and audience-segmented resource lists to help medical and behavioral health service providers better understand how to use OUD medications with their patients and to help patients better understand how OUD medications work. It is for all interested readers.

In Part 5, readers will learn that:

- Practice guidelines and decision-making tools can help healthcare professionals with OUD screening, assessment, diagnosis, treatment planning, and referral.
- Patient- and family-oriented resources provide information about opioid addiction in general; the role of medication, behavioral and supportive services, and mutual-help groups in the treatment of OUD; how-tos for identifying recovery support services; and how-tos for locating medical and behavioral health service providers who specialize in treating OUD or other SUDs.



## EXHIBIT 1.2. Comparison of Medications for OUD

PRESCRIBING CONSIDERATIONS	METHADONE	NALTREXONE	BUPRENORPHINE
<b>Mechanism of Action at mu-Opioid Receptor</b>	Agonist	Antagonist	Partial agonist
<b>Phase of Treatment</b>	Medically supervised withdrawal, maintenance	Prevention of relapse to opioid misuse, following medically supervised withdrawal	Medically supervised withdrawal, maintenance
<b>Route of Administration</b>	Oral	Oral, intramuscular extended-release	Sublingual, buccal, subdermal implant, subcutaneous extended release injection
<b>Possible Adverse Effects</b>	Constipation, hyperhidrosis, respiratory depression, sedation, QT prolongation, sexual dysfunction, severe hypotension including orthostatic hypotension and syncope, misuse potential, neonatal abstinence syndrome	Nausea, anxiety, insomnia, precipitated opioid withdrawal, hepatotoxicity, vulnerability to opioid overdose, depression, suicidality, muscle cramps, dizziness or syncope, somnolence or sedation, anorexia, decreased appetite or other appetite disorders <b>Intramuscular:</b> Pain, swelling, induration (including some cases requiring surgical intervention)	Constipation, nausea, precipitated opioid withdrawal, excessive sweating, insomnia, pain, peripheral edema, respiratory depression (particularly combined with benzodiazepines or other CNS depressants), misuse potential, neonatal abstinence syndrome <b>Implant:</b> Nerve damage during insertion/removal, accidental overdose or misuse if extruded, local migration or protrusion <b>Subcutaneous Injection:</b> Injection site itching or pain, death from intravenous injection
<b>Regulations and Availability</b>	Schedule II; only available at federally certified OTPs and the acute inpatient hospital setting for OUD treatment	Not a scheduled medication; not included in OTP regulations; requires prescription; office-based treatment or specialty substance use treatment programs, including OTPs	Schedule III; requires waiver to prescribe outside OTPs <b>Implant:</b> Prescribers must be certified in the Probuphine Risk Evaluation and Mitigation Strategy (REMS) Program. Providers who wish to insert/remove implants are required to obtain special training and certification in the REMS Program <b>Subcutaneous Injection:</b> Healthcare settings and pharmacies must be certified in the Sublocade REMS Program and only dispense the medication directly to a provider for administration

Adapted with permission.<sup>30</sup> Copyrighted 2017. UBM Medica. 131265:0917SH



## Notes

- 1 Substance Abuse and Mental Health Services Administration. (2017). Recovery and recovery support [Webpage]. Retrieved November 17, 2017, from [www.samhsa.gov/recovery](http://www.samhsa.gov/recovery)
- 2 Council of Economic Advisers. (2017, November). *The underestimated cost of the opioid crisis*. Washington, DC: Executive Office of the President of the United States.
- 3 Substance Abuse and Mental Health Services Administration. (2019). Results from the 2018 National Survey on Drug Use and Health: Detailed tables. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Retrieved January 11, 2020, from <https://www.samhsa.gov/data/>
- 4 Centers for Disease Control and Prevention, National Center for Health Statistics. (2020). *Multiple Cause of Death 1999-2018 on CDC WONDER Online Database, released in 2020*. Retrieved March 12, 2020, from <http://wonder.cdc.gov/mcd-icd10.html>
- 5 National Highway Traffic Safety Administration. (2020). *Fatal Motor Vehicle Crashes. Years: 2018*. Retrieved March 12, 2020, from <https://cdan.dot.gov/SASStoredProcess/guest>
- 6 Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000). A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. *New England Journal of Medicine*, 343(18), 1290–1297.
- 7 Krupitsky, E., Nunes, E. V., Ling, W., Illeperuma, A., Gastfriend, D. R., & Silverman, B. L. (2011, April 30). Injectable extended-release naltrexone for opioid dependence: A double-blind, placebo-controlled, multicentre randomised trial. *Lancet*, 377(9776), 1506–1513.
- 8 Lee, J. D., Friedmann, P. D., Kinlock, T. W., Nunes, E. V., Boney, T. Y., Hoskinson, R. A., Jr., ... O'Brien, C. P. (2016). Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. *New England Journal of Medicine*, 374(13), 1232–1242.
- 9 Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. *Cochrane Database of Systematic Reviews*, 2009(3), 1–19.
- 10 Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. *Cochrane Database of Systematic Reviews*, 2014(2), 1–84.
- 11 Auriacombe, M., Fatséas, M., Dubernet, J., Daulouède, J. P., & Tignol, J. (2004). French field experience with buprenorphine. *American Journal on Addictions*, 13(Suppl. 1), S17–S28.
- 12 Degenhardt, L., Randall, D., Hall, W., Law, M., Butler, T., & Burns, L. (2009). Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: Risk factors and lives saved. *Drug and Alcohol Dependence*, 105(1–2), 9–15.
- 13 Gibson, A., Degenhardt, L., Mattick, R. P., Ali, R., White, J., & O'Brien, S. (2008). Exposure to opioid maintenance treatment reduces long-term mortality. *Addiction*, 103(3), 462–468.
- 14 Schwartz, R. P., Gryczynski, J., O'Grady, K. E., Sharfstein, J. M., Warren, G., Olsen, Y., ... Jaffe, J. H. (2013). Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995–2009. *American Journal of Public Health*, 103(5), 917–922.
- 15 World Health Organization. (2009). *Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence*. Geneva, Switzerland: WHO Press.
- 16 Substance Abuse and Mental Health Services Administration. (2019). Results from the 2018 National Survey on Drug Use and Health: Detailed tables. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Retrieved January 11, 2020, from <https://www.samhsa.gov/data/>
- 17 Department of Health and Human Services, Office of the Surgeon General. (2016). *Facing addiction in America: The Surgeon General's report on alcohol, drugs, and health*. Washington, DC: Department of Health and Human Services.
- 18 Jones, C. M., Campopiano, M., Baldwin, G., & McCance-Katz, E. (2015). National and state treatment need and capacity for opioid agonist medication-assisted treatment. *American Journal of Public Health*, 105(8), e55–e63.
- 19 Jones, C. M., Campopiano, M., Baldwin, G., & McCance-Katz, E. (2015). National and state treatment need and capacity for opioid agonist medication-assisted treatment. *American Journal of Public Health*, 105(8), e55–e63.
- 20 Cartwright, W. S. (2000). Cost-benefit analysis of drug treatment services: Review of the literature. *Journal of Mental Health Policy and Economics*, 3(1), 11–26.
- 21 McCollister, K. E., & French, M. T. (2003). The relative contribution of outcome domains in the total economic benefit of addiction interventions: A review of first findings. *Addiction*, 98(12), 1647–1659.
- 22 Weiss, A. J., Elixhauser, A., Barrett, M. L., Steiner, C. A., Bailey, M. K., & O'Malley, L. (2017, January). *Opioid-related inpatient stays and emergency department visits by state, 2009–2014*. HCUP Statistical Brief No. 219. Rockville, MD: Agency for Healthcare Research and Quality.



- 23 Agency for Healthcare Research and Quality. (2019). Rate of opioid-related ED visits per 100,000 population. Retrieved January 11, 2020, from <https://www.hcup-us.ahrq.gov/faststats/OpioidUseMap?setting=ED>
- 24 U.S. Preventive Services Task Force. (2013). Archived Final Recommendation Statement on Human Immunodeficiency Virus (HIV) Infection: Screening. December 30, 2013. Retrieved January 11, 2020, from: <https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/human-immunodeficiency-virus-hiv-infection-screening#consider>
- 25 Centers for Disease Control and Prevention. (2015). Testing recommendations for hepatitis C virus infection. October 15, 2015. Retrieved January 11, 2020, from: <https://www.cdc.gov/hepatitis/hcv/guidelinesc.htm>
- 26 Weiss, A. J., Elixhauser, A., Barrett, M. L., Steiner, C. A., Bailey, M. K., & O'Malley, L. (2017, January). *Opioid-related inpatient stays and emergency department visits by state, 2009–2014*. HCUP Statistical Brief No.219. Rockville, MD: Agency for Healthcare Research and Quality.
- 27 Agency for Healthcare Research and Quality. (2019). Rate of opioid-related inpatient stays per 100,000 population. Retrieved January 11, 2020, from <https://www.hcup-us.ahrq.gov/faststats/OpioidUseMap?setting=IP>
- 28 World Health Organization. (2009). *Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence*. Geneva, Switzerland: WHO Press.
- 29 Soyka, M., Träder, A., Klotsche, J., Haberthür, A., Bühringer, G., Rehm, J., & Wittchen, H. U. (2012). Criminal behavior in opioid-dependent patients before and during maintenance therapy: 6-year follow-up of a nationally representative cohort sample. *Journal of Forensic Sciences*, 57(6), 1524–1530.
- 30 Brezing, C., & Bisaga, A. (2015, April 30). Opioid use disorder: Update on diagnosis and treatment. *Psychiatric Times*, 32(4) 1–4.

## TIP Development Participants

### Expert Panelists

Each Treatment Improvement Protocol's (TIP's) expert panel is a group of primarily nonfederal addiction-focused clinical, research, administrative, and recovery support experts with deep knowledge of the TIP's topic. With the Substance Abuse and Mental Health Services Administration's (SAMHSA's) Knowledge Application Program (KAP) team, they develop each TIP via a consensus-driven, collaborative process that blends evidence-based, best, and promising practices with the panel's expertise and combined wealth of experience.

#### **TIP Chair**

**Robert P. Schwartz, M.D.—TIP Chair**  
Medical Director/Senior Research Scientist  
Friends Research Institute  
Baltimore, MD

#### **TIP Expert Panelists**

**Sarah Church, Ph.D.**  
Executive Director  
Montefiore Medical Center  
Wellness Center at Waters Place  
Bronx, NY

**Diana Coffa, M.D., FM**  
Associate Professor  
University of California School of Medicine  
Family Community Medicine  
San Francisco, CA

**Zwaantje Hamming, M.S.N., FNP-C, CARN-AP**  
La Familia Medical Center  
Santa Fe, NM

**Ron Jackson, M.S.W., LICSW**  
Affiliate Professor  
University of Washington School of Social Work  
Seattle, WA

**Hendree Jones, Ph.D.**  
Professor and Executive Director  
Horizons Program  
Chapel Hill, NC

**Michelle Lofwall, M.D., DFASAM**  
Medical Director  
University of Kentucky College of Medicine—  
Straus Clinic  
Associate Professor of Behavioral Science and  
Psychiatry  
Faculty in UK Center on Drug and Alcohol  
Research  
Lexington, KY

**Shannon C. Miller, M.D., DFASAM, DFAPA  
(ad hoc panelist)**  
Director, Addiction Services  
Veterans Affairs Medical Center  
Cincinnati, OH

**Charles Schauburger, M.D.**  
Obstetrician-Gynecologist  
Gundersen Health System  
La Crosse, WI

**Joycelyn Woods, M.A., CMA**  
Executive Director  
National Alliance for Medication Assisted  
Recovery  
New York, NY

#### **SAMHSA's TIP Champion**

**Melinda Campopiano von Klimo, M.D.**  
Senior Medical Advisor  
Center for Substance Abuse Treatment  
SAMHSA  
Rockville, MD



## Scientific Reviewers

This TIP's scientific reviewers are among the foremost experts on the three medications discussed in this TIP to treat opioid use disorder. Their role in the collaborative TIP development process was to help the KAP team include current, accurate, and comprehensive information and instructions about the use of each of these medications.

### ***Buprenorphine***

#### **David A. Fiellin, M.D.**

Professor of Investigative Medicine and Public Health  
Yale University School of Medicine  
New Haven, CT

### ***Naltrexone***

#### **Joshua D. Lee, M.D., M.Sc.**

Associate Professor  
Department of Population Health  
Division of General Medicine and Clinical Innovation  
NYU Langone Health  
New York, NY

### ***Methadone***

#### **Andrew J. Saxon, M.D.**

Professor  
Department of Psychiatry and Behavioral Sciences  
University of Washington School of Medicine  
Director  
Center of Excellence in Substance Abuse Treatment and Education  
Veterans Affairs Puget Sound Health Care System  
Seattle, WA

## Field Reviewers

Field reviewers represent each TIP's intended target audiences. They work in addiction, mental health, primary care, and adjacent fields. Their direct front-line experience related to the TIP's topic allows them to provide valuable input on a TIP's relevance, utility, accuracy, and accessibility.

#### **William Bograkos, M.A., D.O., FACOEP, FACOFP**

Adjunct Professor  
Center for Excellence in the Neurosciences  
University of New England (UNE)  
Clinical Professor of Medical Military Science  
Family Practice and Emergency Medicine, UNE  
Biddeford, ME

#### **Meg Brunner, M.L.I.S.**

Librarian, Alcohol and Drug Abuse Institute  
University of Washington  
Seattle, WA

#### **Kathryn Cates-Wessell**

Chief Executive Officer  
American Academy of Addiction Psychiatry  
East Providence, RI

#### **Mary Catlin, BSN, M.P.H., CIC**

Public Health Nurse  
Alcohol and Drug Abuse Institute  
University of Washington  
Seattle, WA

#### **Kelly J. Clark, M.D., M.B.A., DFASAM**

President  
American Society of Addiction Medicine  
Rockville, MD

#### **Marc Fishman, M.D.**

Assistant Professor  
Johns Hopkins University School of Medicine,  
Psychiatry/Behavioral Sciences Expert Team  
Baltimore, MD

#### **Katherine Fornili, D.N.P., M.P.H., RN, CARN**

Assistant Professor  
University of Maryland School of Nursing  
Baltimore, MD

**Adam Gordon, M.D., M.P.H., FACP, FASAM, CMRO**

Associate Professor of Medicine and Advisory Dean  
University of Pittsburgh School of Medicine  
Pittsburgh, PA

**Ellie Grossman, M.D.**

Instructor in Medicine  
Cambridge Health Alliance  
Somerville Hospital Primary Care  
Somerville, MA

**Kyle Kampman, M.D.**

Professor, Department of Psychiatry  
Perelman School of Medicine  
University of Pennsylvania  
Center for Studies of Addiction  
Philadelphia, PA

**Janice Kauffman, M.P.H., RN, CAS, CADC-1**

Vice President of Addiction Treatment Services,  
North Charles Foundation, Inc.  
Director of Addictions Consultation, Department  
of Psychiatry, Cambridge Health Alliance  
Assistant Professor of Psychiatry, Harvard  
Medical School, the Cambridge Hospital  
Cambridge, MA

**Jason Kletter, Ph.D.**

President, Bay Area Addiction Research and  
Treatment  
President, California Opioid Maintenance  
Providers  
San Francisco, CA

**William J. Lorman, J.D., Ph.D., MSN, PMHNP-BC, CARN-AP**

Vice President and Chief Clinical Officer  
Livengrin Foundation, Inc.  
Bensalem, PA

**Megan Marx-Varela, M.P.A.**

Associate Director  
The Joint Commission—Behavioral Health Care  
Accreditation  
Oakbrook Terrace, IL

**Alison Newman, M.P.H.**

Continuing Education Specialist  
Alcohol and Drug Abuse Institute  
University of Washington  
Seattle, WA

**David O’Gurek, M.D., FAAFP**

Assistant Professor  
Family and Community Medicine, Lewis Katz  
School of Medicine  
Temple University  
Philadelphia, PA

**Yngvild Olsen, M.D., M.P.H, FASAM**

Medical Director  
Institutes for Behavior Resources, Inc./Recovery  
Enhanced by Access to Comprehensive  
Healthcare (REACH) Health Services  
Baltimore, MD

**Shawn A. Ryan, M.D., M.B.A., ABEM, FASAM**

President & Chief Medical Officer  
BrightView  
Cincinnati, OH

**Paul Stasiewicz, Ph.D.**

Senior Research Scientist  
Research Institute on Addictions  
State University of New York-Buffalo  
Buffalo, NY

**Kenneth Stoller, M.D.**

Director  
Broadway Center for Addiction at the Johns  
Hopkins Hospital  
Assistant Professor of Psychiatry and Behavioral  
Sciences  
Johns Hopkins University  
Baltimore, MD

**Mishka Terplan, M.D., M.P.H., FACOG**

Professor  
Department of Obstetrics and Gynecology,  
Division of General Obstetrics and Gynecology  
Virginia Commonwealth University  
Richmond, VA

**Christopher Welsh, M.D.**

Associate Professor of Psychiatry  
University of Maryland Medical Center  
Baltimore, MD

**George E. Woody, M.D.**

Professor of Psychiatry  
Department of Psychiatry Center for Studies of  
Addiction  
University of Pennsylvania’s Perelman School of  
Medicine  
Philadelphia, PA



## Publication Information

### Acknowledgments

This publication was prepared under contract number 270-14-0445 by the Knowledge Application Program (KAP) for the Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration (SAMHSA), U.S. Department of Health and Human Services (HHS). Suzanne Wise served as the Contracting Officer's Representative, and Candi Byrne served as KAP Project Coordinator.

### Disclaimer

The views, opinions, and content expressed herein are the views of the consensus panel members and do not necessarily reflect the official position of SAMHSA or HHS. No official support of or endorsement by SAMHSA or HHS for these opinions or for the instruments or resources described is intended or should be inferred. The guidelines presented should not be considered substitutes for individualized client care and treatment decisions.

### Public Domain Notice

All materials appearing in this publication except those taken directly from copyrighted sources are in the public domain and may be reproduced or copied without permission from SAMHSA or the authors. Citation of the source is appreciated. However, this publication may not be reproduced or distributed for a fee without the specific, written authorization of the Office of Communications, SAMHSA, HHS.

### Electronic Access and Copies of Publication

This publication may be ordered or downloaded from SAMHSA's Publications Ordering webpage at <https://store.samhsa.gov>. Or, please call SAMHSA at 1-877-SAMHSA-7 (1-877-726-4727) (English and Español).

### Recommended Citation

Substance Abuse and Mental Health Services Administration. *Medications for Opioid Use Disorder*. Treatment Improvement Protocol (TIP) Series 63, Executive Summary. Publication No. PEP20-02-01-005. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2020.

### Originating Office

Quality Improvement and Workforce Development Branch, Division of Services Improvement, Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, 5600 Fishers Lane, Rockville, MD 20857.

### Nondiscrimination Notice

SAMHSA complies with applicable federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. SAMHSA cumple con las leyes federales de derechos civiles aplicables y no discrimina por motivos de raza, color, nacionalidad, edad, discapacidad, o sexo.

Publication No. PEP20-02-01-005  
First released 2018. Revised 2019 and 2020.